8-K

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 10, 2011

HUMAN GENOME SCIENCES, INC.
(Exact name of registrant as specified in its charter)

Delaware	001-14169	22-3178468
(State or other Jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification No.)

14200 Shady Grove Road, Rockville, Maryland	20850-7464
(Address of Principal Executive Offices)	(Zip Code)

Registrant’s telephone number, including area code: (301) 309-8504

(Former name or former address if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 2.02. Results of Operations and Financial Condition.

On January 10, 2011, the Company issued the press release attached as Exhibit 99.1 to this Form 8-K, which includes priority goals for 2011 and a business update and reaffirms the Company’s previously disclosed guidance regarding cash and investments at year-end 2010.

Item 7.01. Regulation FD Disclosure.

During the week of January 10, 2011, representatives of Human Genome Sciences, Inc. will be attending meetings with investors, analysts and others at the J.P. Morgan Healthcare Conference in San Francisco, California, and will be presenting at the conference on Monday, January 10, 2011, at 3:30 p.m. Pacific time (6:30 p.m. Eastern time). During these meetings and the presentation, the Company will present the slides attached as Exhibit 99.2 to this Form 8-K.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

99.1 Press Release, dated January 10, 2011

99.2 Slide Presentation, dated January 10, 2011

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

HUMAN GENOME SCIENCES, INC.

By: /s/ James H. Davis, Ph.D.
Name: James H. Davis, Ph.D.
Title: Executive Vice President, General
Counsel and Secretary

Date: January 10, 2011

INDEX TO EXHIBITS

Exhibit No.	Description
99.1	Press Release, dated January 10, 2011
99.2	Slide Presentation, dated January 10, 2011

EX-99.1

Exhibit 99.1

PRESS RELEASE

Media Contacts:	Investor Contacts:
Jerry Parrott	Claudine Prowse, Ph.D.
Vice President, Corporate Communications	Executive Director, Investor Relations
301-315-2777	301-315-1785
Susannah Budington	Peter Vozzo
Director, Corporate Public Relations	Senior Director, Investor Relations
301-545-1062	301-251-6003

HUMAN GENOME SCIENCES REPORTS PROGRESS TOWARD SUSTAINABLE REVENUES AND ANNOUNCES 2011 GOALS AT JPMORGAN HEALTHCARE CONFERENCE

• President and CEO H. Thomas Watkins sets goal of multi-billion dollar annual revenues by 2015

• HGS well prepared for successful launch of BENLYSTA^®, potentially the first approved drug for lupus in more than 50 years

ROCKVILLE, Maryland — January 10, 2011 — Human Genome Sciences, Inc. (Nasdaq: HGSI) today will announce its priority goals for 2011 and provide updates on the Company’s progress toward becoming a fully commercial organization with sustainable revenues and multiple opportunities to drive future growth. The presentation will be made this afternoon by H. Thomas Watkins, President and Chief Executive Officer, to financial analysts and investors at the 29^th Annual JPMorgan Healthcare Conference in San Francisco.

“Based on the opportunities we have in hand and our expectation of U.S. and European regulatory approvals of BENLYSTA, we believe HGS will achieve sustainable multi-billion dollar annual revenues by 2015,” said Mr. Watkins. “2011 will be a game-changing year for us assuming approval and launch of BENLYSTA as the first new drug for lupus in over 50 years. HGS has systematically hired and carefully trained a specialized commercial team that we believe is second to none in their experience and familiarity with rheumatology, biologics and infused products. We are ready to hit the ground running alongside GlaxoSmithKline following FDA approval of BENLYSTA.”

“We are also fully committed to achieving the full therapeutic and commercial potential of BENLYSTA by developing it for other B-cell mediated diseases where patients need new therapeutic options and strong scientific evidence supports therapeutic potential and commercial viability,” he added. “In 2011, we plan to initiate Phase 2 trials of BENLYSTA in vasculitis and post-renal transplant, as well as a Phase 3 trial of a subcutaneous formulation of BENLYSTA.”

Mr. Watkins added that HGS will continue to invest strategically in its oncology and other pipeline opportunities. “These strategic investments are made possible by a strong financial position that we view as essential to our ability to achieve sustainable revenues and sustainable growth into the future,” he said.

During his presentation, Mr. Watkins will discuss the following goals and updates on progress:

BENLYSTA^® for Systemic Lupus Erythematosus (SLE): Target Date for FDA Decision on U.S. Approval March 10, 2011; Specialized HGS Commercial Team Hired and Trained; European Regulatory Decision Anticipated Second Half 2011; Building European Organization to Work Alongside GSK in Key Countries

On November 16, 2010, the FDA Arthritis Advisory Committee voted 13-2 to recommend that the FDA approve BENLYSTA (belimumab) for the treatment of autoantibody-positive patients with active SLE who are receiving standard therapy. Following the Advisory Committee meeting, the FDA requested additional information from HGS, which the Company has submitted. In December 2010, the FDA extended the Prescription Drug User Fee Act (PDUFA) target date for the priority review of BENLYSTA to March 10, 2011.

BENLYSTA is an investigational drug and the first in a new class of drugs called BLyS-specific inhibitors. HGS and GSK are developing BENLYSTA under a definitive co-development and co-commercialization agreement entered into in 2006.

In preparation for the successful launch and commercialization of BENLYSTA assuming regulatory approval, HGS has systematically hired and trained a specialized team including sales, marketing and medical affairs. The combined HGS and GSK team, including a U.S. sales force of approximately 150, will work closely together following approval to communicate effectively and appropriately with rheumatologists and other stakeholders and ensure that appropriate patients with systemic lupus who need BENLYSTA will have access to it. HGS and GSK also plan to support physicians and patients with reimbursement and access programs.

2

Under the terms of the 2006 co-development and co-commercialization agreement with GSK, HGS has responsibility for the global supply of BENLYSTA upon receiving regulatory approvals. HGS currently has inventory available to meet global market needs for at least one year, and its large-scale manufacturing facility has sufficient capacity to provide worldwide supply for the first two to three years following launch. However, HGS and GSK also anticipate that additional capacity will be required. In July 2010, HGS announced an agreement with Lonza that will provide for the future commercialization of BENLYSTA, eventually tripling capacity with production coming on line in 2012.

HGS and GSK expect to receive European approval of BENLYSTA in the second half of 2011. GSK has also submitted regulatory applications in Canada, Australia, Switzerland, Russia and Brazil. Regulatory submissions in other countries are planned in 2011. HGS is building its own commercialization team to work alongside GSK in Europe, with headquarters in Switzerland and local organizations in Germany, France and Spain. Elsewhere, GSK will lead local implementation, with HGS sharing costs and profits equally with GSK.

Key goals for BENLYSTA in 2011:

• FDA approval and U.S. launch.

• European approval and launch.

• Initiate Phase 3 trial of subcutaneous formulation.

• Initiate Phase 2 trials in vasculitis and post-renal transplant.

Raxibacumab: Deliveries to U.S. Strategic National Stockpile Continue under Second BARDA Contract

In July 2009, the U.S. Government exercised its option to purchase an additional 45,000 doses of raxibacumab for the U.S. Strategic National Stockpile for emergency use in treating inhalation anthrax, with delivery to be completed over a three-year period. HGS expects to receive approximately $142 million from this second award as deliveries are completed, including approximately $51 million received in 2010.

3

Raxibacumab is being developed under a contract entered into in 2006 with the Biomedical Advanced Research and Development Authority (BARDA) of the Office of the Assistant Secretary for Preparedness and Response (ASPR), U.S. Department of Health and Human Services (HHS). HGS continues to work closely with FDA to achieve licensure of raxibacumab. HGS is entitled to receive $20 million under its contract with the U.S. Government upon FDA licensure.

Key goals for raxibacumab in 2011:

• Deliver 15,000 doses to the U.S. Strategic National Stockpile and receive approximately $50 million in revenue as deliveries are accepted.

• Continue to work with the FDA to achieve licensure of raxibacumab.

Mid- and Early-Stage Pipeline: A Primary Focus on Immunology and Oncology

HGS is investing strategically to expand and advance its mid- and early-stage pipeline beyond potential additional indications for BENLYSTA, with a primary focus on immunology and oncology. The Company is developing its oncology portfolio around its expertise in the apoptosis, or programmed cell death, pathway, and also plans to initiate Phase 2 development of its human monoclonal antibody to the CCR5 receptor for the treatment of ulcerative colitis.

Mapatumumab, a human monoclonal antibody to TRAIL receptor 1, is currently being studied in combination with Nexavar (sorafenib) for the treatment of advanced hepatocellular cancer.

Ongoing Phase 1 trials are evaluating HGS1029 as monotherapy in patients with advanced solid and advanced lymphoid tumors. HGS1029 is an IAP inhibitor, a novel class of compounds that block the activity of IAP (inhibitor of apoptosis) proteins, allowing apoptosis to proceed and causing the cancer cells to die. When IAP proteins are over-expressed in cancer cells, they can help cancer cells resist apoptosis and resume growth and proliferation. HGS plans to continue the study of HGS1029 both alone and in combination with other anti-cancer agents, including mapatumumab.

Key goals for the HGS mid- and early-stage pipeline in 2011 are:

• Continue the clinical trial of mapatumumab with sorafenib in advanced hepatocellular cancer.

• Initiate Phase 1b oncology studies of HGS1029 in combination with mapatumumab and other agents.

• Complete Phase 1 trials of HGS1029 as monotherapy in advanced solid and lymphoid tumors.

• Initiate Phase 2 trial of CCR5 mAb in ulcerative colitis.

4

GSK Pipeline: Two Phase 3 Trials of Darapladib Ongoing for the Treatment of Cardiovascular Disease; Eight Phase 3 Trials of Albiglutide Ongoing for the Treatment of Type 2 Diabetes Mellitus

In two pivotal Phase 3 trials, GSK is currently evaluating whether darapladib can reduce the risk of adverse cardiovascular events such as heart attack or stroke in patients with chronic coronary heart disease and acute coronary syndrome, respectively. With a planned enrollment of more than 27,000 patients in the two trials, the Phase 3 clinical program for darapladib is among the largest ever conducted to evaluate the safety and efficacy of any cardiovascular medication. Darapladib was discovered by GSK based on HGS technology. HGS will receive 10% royalties on worldwide sales if darapladib is commercialized, and has a 20% co-promotion option in North America and Europe.

GSK now has eight Phase 3 trials in progress to evaluate the long-term efficacy, safety and tolerability of albiglutide as monotherapy and add-on therapy for patients with type 2 diabetes mellitus. Albiglutide was created by HGS using its proprietary albumin-fusion technology, and the product was licensed to GSK in 2004. HGS is entitled to fees and milestone payments that could amount to as much as $183 million — including $33 million received to date — in addition to single-digit royalties on worldwide sales if albiglutide is commercialized.

2010 Financial Guidance

HGS expects cash and investments at year-end 2010 to total between $900 million and $950 million. Cash and investments were approximately $1.2 billion at the end of 2009, which included net proceeds from successful public offerings of HGSI common stock.

Presentation to Be Webcast

Mr. Watkins’ presentation to the 29^th Annual JPMorgan Healthcare Conference will be webcast and may be accessed at www.hgsi.com. The presentation is scheduled to begin on January 10, 2011, at 3:30 PM Pacific or 6:30 PM Eastern time. Investors interested in listening to the live webcast may want to log on before the presentation begins to download any software required. The archive of the presentation will be available for several days following the event.

About Human Genome Sciences

Human Genome Sciences exists to place new therapies into the hands of those battling serious disease.

5

For more information about HGS, please visit the Company’s web site at www.hgsi.com. Health professionals and patients interested in clinical trials of HGS products may inquire via e-mail to medinfo@hgsi.com or by calling HGS at (877) 822-8472. HGS, Human Genome Sciences and BENLYSTA are trademarks of Human Genome Sciences, Inc. Other trademarks referenced are the property of their respective owners.

Safe Harbor Statement

This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The forward-looking statements are based on Human Genome Sciences’ current intent, belief and expectations. These statements are not guarantees of future performance and are subject to certain risks and uncertainties that are difficult to predict. Actual results may differ materially from these forward-looking statements because of Human Genome Sciences’ unproven business model, its dependence on new technologies, the uncertainty and timing of clinical trials and regulatory approvals, Human Genome Sciences’ ability to develop and commercialize products, its dependence on collaborators for services and revenue, its substantial indebtedness and lease obligations, its changing requirements and costs associated with facilities, intense competition, the uncertainty of patent and intellectual property protection, Human Genome Sciences’ dependence on key management and key suppliers, the uncertainty of regulation of products, the impact of future alliances or transactions and other risks described in the Company’s filings with the SEC. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of today’s date. Human Genome Sciences undertakes no obligation to update or revise the information contained in this announcement whether as a result of new information, future events or circumstances or otherwise.

# # #

6

EX-99.2

Exhibit 99.2

BENLYSTA(r) AND BEYOND H. Thomas Watkins President and Chief Executive Officer JP Morgan Healthcare Conference January 10, 2011

NOTE REGARDING FORWARD-LOOKING STATEMENTS 2 JPMorgan Healthcare Conference | January 10, 2011 This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The forward-looking statements are based on Human Genome Sciences' current intent, belief and expectations. These statements are not guarantees of future performance and are subject to certain risks and uncertainties that are difficult to predict. Actual results may differ materially from these forward-looking statements because of Human Genome Sciences' unproven business model, its dependence on new technologies, the uncertainty and timing of clinical trials and regulatory approvals, Human Genome Sciences' ability to develop and commercialize products, its dependence on collaborators for services and revenue, its substantial indebtedness and lease obligations, its changing requirements and costs associated with facilities, intense competition, the uncertainty of patent and intellectual property protection, Human Genome Sciences' dependence on key management and key suppliers, the uncertainty of regulation of products, the impact of future alliances or transactions and other risks described in the Company's filings with the SEC. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of today's date. Human Genome Sciences undertakes no obligation to update or revise the information contained in this presentation whether as a result of new information, future events or circumstances or otherwise. HGS, Human Genome Sciences, and BENLYSTA are trademarks of Human Genome Sciences, Inc. Other trademarks referenced are the property of their respective owners.

BROAD POTENTIAL BEYOND INITIAL MARKET ENTRY IN SLE 3 JPMorgan Healthcare Conference | January 10, 2011 Drivers of Near-Term Growth Drivers of Long-Term Growth

Drivers of Near-Term Growth BENLYSTA: potentially improves standard of care for SLE First Phase 3 trials to achieve primary endpoint in SLE Positive FDA Ad Comm vote for approval (13-2); New PDUFA target March 10, 2011 Initial U.S. market-200,000 patients with moderate-to-severe systemic lupus Specialty sales force targeting key physicians Global alliance with GSK Strong cash position-estimated $900-950 million as of December 31, 2010 A FORMULA FOR SUSTAINED GROWTH 4 JPMorgan Healthcare Conference | January 10, 2011

A FORMULA FOR SUSTAINED GROWTH 5 Drivers of Long-Term Growth BENLYSTA: potential indications* Vasculitis ~175,000 U.S. patients Transplant ~235,000 U.S. patients (total prevalence, pre- and post-) Sjogren's syndrome ~156,000 severe, diagnosed U.S. patients Waldenstrom's disease ~8,000 U.S. patients ITP ~50-100,000 U.S. patients; ~60,000 EU patients Raxibacumab for inhalation anthrax GSK pipeline, Phase 3s ongoing: Darapladib-cardiovascular Albiglutide-type 2 diabetes Oncology program, Phase 1/2 ongoing CCR5 mAb-ulcerative colitis, Phase 2 initiation planned 2011 World-class biologics manufacturing capability *The populations here are not intended to imply an expectation that all of these indications will be developed or approved by regulatory agencies.

6 JPMorgan Healthcare Conference | January 10, 2011 POTENTIALLY IMPROVES STANDARD OF CARE FOR SLE

Potential to be the first drug approved for SLE in 50 years High unmet need Global alliance with GSK Targeted commercial strategy BENLYSTA(r) NEAR TERM OPPORTUNITY SLE THE MEANINGFUL DRIVER 7 JPMorgan Healthcare Conference | January 10, 2011

SLE IS A SYSTEMIC DISEASE AFFECTING MULTIPLE ORGANS 8 JPMorgan Healthcare Conference | January 10, 2011 A chronic, life-threatening autoimmune disease resulting from excess autoantibody production Multiple organ systems often affected simultaneously Skin, joint and immunologic most common Symptoms include severe pain, extreme fatigue, swollen joints, skin rash and kidney problems Mortality rate 2-5x normal Eyes and Mucous Membranes Heart and Lungs Skin Gastrointestinal System Reproductive System Musculoskeletal System Joints Kidneys Central Nervous System Blood

Mild 33% Severe 22% Moderate 45% Initial Target 200,000 1,500,000 Patients with Lupus and Related Conditions* 325,000 SLE Patients Treated by Rheumatologists** * Per Lupus Foundation of America ** Per primary market research BENLYSTA(r) INITIAL U.S. MARKET: 200,000 PATIENTS 9 JPMorgan Healthcare Conference | January 10, 2011

Met primary endpoint in two Phase 3 trials Reduction of disease activity over and above standard therapy Signals of other potential benefits Reduced use of steroids and risk of severe SLE flare rates Improved quality of life Normalized serological activity Nearly 2,000 patients studied for SLE Up to 6 years in Phase 2 continuation studies Administered with wide range of standard therapies SAFETY: Rates of overall adverse events, serious and/or severe adverse events, all infections, serious and/or severe infections, and discontinuations due to adverse events were comparable in Phase Three trials between BENLYSTA and placebo BENLYSTA(r) STUDY PROGRAM FIRST SUCCESSFUL PHASE 3 TRIALS FOR SLE 10

BENLYSTA(r) STUDY PROGRAM STUDY POPULATION REPRESENTATIVE OF MAJORITY OF SLE PATIENTS 11 JPMorgan Healthcare Conference | January 10, 2011 Patients included in the trials had active SLE Autoantibody positive (ANA or anti-dsDNA) SELENA SLEDAI score ^6 Most on 2 or more stable therapies Patients excluded from the trials At risk for acute intervention with highly aggressive therapy Severe active lupus kidney disease Severe active CNS disease (including seizures, psychosis)

Bringing BENLYSTA(r) to Patients 12 JPMorgan Healthcare Conference | January 10, 2011

Patients Selected for BENLYSTA TARGETING ALL STAKEHOLDERS 13 JPMorgan Healthcare Conference | January 10, 2011 13 Education/Patient Selection Pull Through/Support Healthcare Professionals Sales Force Promotion Education and Drug Information Reimbursement Services Staff Education Patient Education & Persistence Patient Assistance and Copay Program Reimbursement Support Patients Educate Patients about SLE and Treatment Options www.usinlupus.com Payers Encourage Appropriate Access Coverage Policies

SPECIALTY SALES FORCE TARGETS KEY PHYSICIANS ~150 total U.S. sales reps, shared equally by HGS and GSK Former employers include Abbott, Amgen, Biogen, Bristol-Myers Squibb, Centocor, Genentech, Eisai, Wyeth Significant experience with rheumatology biologics, including Remicade, Rituxan, Orencia, Enbrel, Actemra Building HGS presence in Europe to commercialize BENLYSTA along with GSK HGS operating teams in Germany, France and Spain EU headquarters in Switzerland 3 Area Directors 10 District Managers ~70 U.S. sales representatives HGS U.S. 14 JPMorgan Healthcare Conference | January 10, 2011

OPTIMIZING ACCESS TO BENLYSTA(r) A KEY PRIORITY BENLYSTA will primarily be covered under the Medical Benefit Access broader in scope than Pharmacy Benefit Payers establish policies for product access Prior authorization requirements GSK Payer Account Managers support coverage policy determination SLE education and product information on BENLYSTA Proactive in defining appropriate patient types Encourage appropriate prior authorization requirements 15 JPMorgan Healthcare Conference | January 10, 2011

Patient identified/ verify benefits Secure prior auth (if required) Schedule patient; order drug File claim Reimbursement from payer HGS SUPPORTS PHYSICIAN AND PATIENT ACCESS State-of-the-Art Programs (largely via third parties) Educate and facilitate appropriate physician reimbursement Benefit verification/prior authorization assistance Billing, coding and claims-tracking assistance Support patient access to BENLYSTA Financial assistance for uninsured Out-of-pocket cost programs for commercially insured 16 JPMorgan Healthcare Conference | January 10, 2011

PRICING BENLYSTA(r) RIGHT FOR THE MARKET Pricing Considerations Pricing in comparable categories Quantitative price sensitivity research Economic burden of disease analysis Pharmacoeconomic modeling U.S. Price Comparators HGS and GSK to announce pricing decision close to launch MS Drugs RA Drugs 17 JPMorgan Healthcare Conference | January 10, 2011

MANUFACTURING SUPPLY TO MEET DEMAND - HGS READY TO DELIVER; LONZA TO TRIPLE CAPACITY 18 JPMorgan Healthcare Conference | January 10, 2011

BENLYSTA(r) LONG TERM OPPORTUNITY POTENTIAL TO TARGET ADDITIONAL THERAPEUTIC AREAS 19 JPMorgan Healthcare Conference | January 10, 2011 1U.S. and top 5 largest European markets. 2U.S. only. 3Severe, diagnosed U.S. patients only. 4Worldwide. Source: HGS/GSK estimates. The populations provided here are not intended to imply an expectation that all of these indications will be developed or approved by regulatory agencies. SLE1 Vasculitis2 Post-Renal Transplant2 Sjogren's3/Waldenstrom's4 Pre-Transplant2 ITP1 450,000 625,000 760,000 950,000 1,000,000 1,150,000 PATIENTS

Proof-of-Concept Studies Sjogren's Syndrome Waldenstrom's Disease Pre-transplant ITP Myasthenia gravis Idiopathic membranous nephropathy BROAD POTENTIAL BEYOND INITIAL MARKET ENTRY IN SLE Subcutaneous Formulation May improve convenience for some patients Multi-Center Phase 2 Trials Initiation planned in 2011: Vasculitis Post-renal transplant Post-Approval SLE Studies Large-scale observational trial to track: Potential rare adverse events Real-world outcomes Specific patient groups 20 JPMorgan Healthcare Conference | January 10, 2011

Beyond 21 JPMorgan Healthcare Conference | January 10, 2011

MID-STAGE HGS PIPELINE, LATE-STAGE GSK PRODUCTS PROMISE FUTURE GROWTH POTENTIAL 22 BENLYSTA(r) Anti-CCR5 mAb HGS-1029 BENLYSTA BENLYSTA BENLYSTA Raxibacumab Mapatumumab Darapladib Systemic Lupus1, 2 Ulcerative Colitis3 Cancer Additional Autoimmune Vasculitis3 Post-Renal Transplant3 Inhalation Anthrax Cancer Type 2 Diabetes Cardiovascular Disease BLA Filed Albiglutide

First 20,000 doses delivered H1 2009 to the U.S. Strategic National Stockpile; $163 million in revenue recognized through Q2 2009 45,000 more doses to be delivered over a three-year period; $142 million award; initiated 4Q09 $52 million revenue recognized during the 12 months ended September 30, 2010 RAXIBACUMAB TREATMENT FOR INHALATION ANTHRAX 23 JPMorgan Healthcare Conference | January 10, 2011

Discovered by GSK based on HGS technology 10% royalty on worldwide sales 20% co-promotion option in North America and Europe CV disease one of the largest markets in the pharmaceutical industry DARAPLADIB PHASE 3 FOR CARDIOVASCULAR DISEASE 24 JPMorgan Healthcare Conference | January 10, 2011 Lp-PLA2 inhibitor as a potential anti-atherosclerosis agent for cardiovascular disease Two Phase 3 trials to evaluate Major Adverse Cardiovascular Events (MACE) STABILITY: 15,000+ patients; 39 countries; initiated December 2008; fully enrolled SOLID-TIMI 52: ~11,500 patients in 40 countries; initiated December 2009

Licensed to GSK Fees and milestone payments up to $183 million; up to $150 million still to be received Single-digit net royalties on worldwide sales Approximately 17.9 million diagnosed type 2 diabetes patients in the U.S.1 ALBIGLUTIDE PHASE 3 FOR TYPE 2 DIABETES 25 JPMorgan Healthcare Conference | January 10, 2011 Once-a-week GLP-1 agonist Eight Phase 3 studies ongoing to evaluate efficacy and safety as mono- and add-on therapy in patients with type 2 diabetes First Phase 3 clinical trial initiated 1Q09; expected study duration of up to 3 years 1National Diabetes Fact Sheet, 2007, Centers for Disease Control and Prevention

TRAIL PATHWAY OFFERS THERAPEUTIC OPPORTUNITIES ACROSS A BROAD RANGE OF CANCERS 26 JPMorgan Healthcare Conference | January 10, 2011 Mapatumumab (HGS-ETR1) Targets TRAIL apoptosis pathway Q1 2011 initiation of randomization stage-Phase 2 chemotherapy combo trial in hepatocellular cancer HGS1029 (IAP inhibitor) Novel intracellular target in apoptosis pathway Synergistic preclinical activity demonstrated with mapatumumab and other therapeutic agents Currently in Phase 1 trials as monotherapy-advanced solid and lymphoid tumors Initiating Phase 1b combination oncology studies Q4 2011 HGS1029 HGS-ETR1

Cash and investments at Sept 30, 2010: $1.0 billion Expected net cash burn 2010: $300-$350 million Expected cash and investments at year-end 2010: $900-950 million Products Nearing Commercialization High-Potential Pipeline STRONG FINANCIAL POSITION TO FUEL PRODUCT LAUNCHES, PIPELINE ADVANCEMENT 27 JPMorgan Healthcare Conference | January 10, 2011 Strong Cash Position

Potential Blockbuster Product Pipeline to Fuel Future Growth Manufacturing Excellence Commercial Readiness World-Class Partner Seasoned Leadership A FORMULA FOR SUSTAINABLE GROWTH 28 JPMorgan Healthcare Conference | January 10, 2011 Building Shareholder Value

The End 29